Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and other eye health products under the TheraTears name through chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. This segment offers ophthalmic products, such as AzaSite, an azithromycin ophthalmic solution; Cosopt, a dorzolamide hydrochloride and timolol maleate ophthalmic solution; and Cosopt PF, a preservative-free prescription version of Cosopt. The Hospital Drugs & Injectables segment provides hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. The Contract Services segment manufactures various pharmaceutical products for third party pharmaceutical customers based on their specifications. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Covenant Transportation Group, Inc., together with its subsidiaries, offers truckload transportation and brokerage services in the continental United States. Its Asset-Based Truckload Services segment provides long haul, dedicated, temperature-controlled, and regional solo-driver services. The company also offers freight brokerage services directly, as well as through freight brokerage agents; less-than-truckload consolidation services; and accounts receivable factoring services. It serves transportation companies, such as freight forwarders, less-than-truckload carriers, and third-party logistics providers, as well as traditional truckload customers, including manufacturers, retailers, and food and beverage shippers. As of December 31, 2013, the company operated 2,688 tractors and 6,861 trailers. Covenant Transportation Group, Inc. was founded in 1994 and is headquartered in Chattanooga, Tennessee.
Knight Transportation, Inc., together with its subsidiaries, operates as a short to medium-haul truckload carrier of general commodities primarily in the United States. The company operates in two segments, Asset-Based and Non-Asset-Based. The Asset-Based segment provides truckload carrier dry van; temperature-controlled (refrigerated); dedicated truckload; and drayage services between ocean ports, rail ramps, and shipping docks. The Non-Asset-Based segment provides logistics, freight management, freight brokerage, rail intermodal, and other non-trucking services. As of December 31, 2013, it operated 3,537 company-owned tractors, as well as had 452 tractors under contract that are owned and operated by independent contractors, as well as operated an average of 9,406 trailers. Knight Transportation, Inc. was founded in 1989 and is headquartered in Phoenix, Arizona.
RadNet, Inc. provides outpatient diagnostic imaging services in the United States. The company offers various imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures. It also provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. In addition, the company develops and sells computerized systems for the imaging industry, including picture archiving communications and radiology information systems, and related workflow solutions for hospitals, teleradiology businesses, imaging centers, and specialty physician groups to distribute, visualize, store, and retrieve digital images taken from various diagnostic imaging modalities. As of April 9, 2014, it operated a network of 250 owned and/or operated outpatient imaging centers primarily in California, Maryland, Delaware, New Jersey, New York, and Rhode Island. The company was founded in 1985 and is headquartered in Los Angeles, California.
AAC Holdings, Inc. provides substance abuse treatment services. It offers treatment services for behavioral health disorders. The company also provides detoxification, residential treatment, partial hospitalization, and intensive outpatient care services. AAC Holdings, Inc. was incorporated in 2014 and is headquartered in Brentwood, Tennessee.
AU Optronics Corp. is engaged in the design, development, production, assembly, and marketing of thin film transistor liquid crystal displays and other flat panel displays. The company operates in two segments, Display and Solar. The Display segment offers a range of display panels for use in mobile PCs, such as notebooks and tablets; desktop monitors; consumer electronics products consisting of mobile phones, digital still cameras, portable navigation displays, digital camcorders, automobile displays, amusement and printer displays, and portable gaming consoles; and LCD televisions. This segment sells its panels to original equipment manufacturing service providers who manufacture products on a contract basis for brand companies; and to brand companies on a direct shipment basis. The Solar segment manufactures upstream and midstream products, such as polysilicons, ingots, wafers, and solar cells; designs, develops, and manufactures solar photovoltaic (PV) modules; produces solar PV systems; and provides various value-added services for solar PV systems projects. The company operates in Taiwan, the People's Republic of China, Japan, Singapore, the United States, Korea, and internationally. AU Optronics Corp. was founded in 1996 and is based in Hsinchu, Taiwan.
Federated National Holding Company, through its subsidiaries, is engaged in the insurance underwriting, distribution, and claims processing in the United States. It underwrites homeowners' multi-peril, commercial general liability, federal flood, workers compensation, personal umbrella, inland marine, fire, allied lines, personal and commercial automobile, and other lines of insurance. Federated National Holding Company markets and distributes its own and third-party insurers' products and other services through contractual relationships with independent agents and general agents. The company was formerly known as 21st Century Holding Company and changed its name to Federated National Holding Company in September 2012. Federated National Holding Company was founded in 1991 and is based in Sunrise, Florida.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Sonic Corp. operates and franchises a chain of quick-service drive-in restaurants in the United States. As of January 07, 2014, it operated approximately 3,500 drive-in restaurants in 44 states. It also leases signs and real estate. The company was founded in 1953 and is headquartered in Oklahoma City, Oklahoma.